Pfizer Inc. has agreed to buy Arena Pharmaceuticals Inc. in a deal valued at about $6.7 billion, gaining potential therapies targeting immuno-inflammatory diseases.
To read the entire story, you must be logged in.
Please log in now or register with us.
